Huadong Medicine (SHE:000963) subsidiary Zhongmei Huadong obtained the approval of China's drug regulator to conduct clinical trials of HDM2005 in combination with PD-1 and AD chemotherapy for classical Hodgkin's lymphoma.
The drug is already in trials for multiple hematologic and solid tumor indications in China and the U.S., according to a Thursday filing with the Shenzhen bourse.
Shares of the drugmaker declined 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments